BioStock: Alligator Bioscience’s CEO looks ahead

Recently, Lund-based Alligator Bioscience delivered its report for the first quarter of 2022. Financially, the company stands on solid ground after two capital rounds in 2021 raising 343 MSEK. Operationally, the phase II trial with mitazalimab is progressing according to plan, and ATOR-1017, the second leading project has presented promising data supporting further development steps. BioStock contacted CEO Søren Bregenholt for a comment and an outlook.

Read the interview with Alligator Bioscience's CEO Søren Bregenholt at biostock.se:

https://www.biostock.se/2022/05/alligator-biosciences-ceo-looks-ahead/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/